Vehicle

Preclinical

Vehicle is one of 2 therapeutic programs targeting Generalized Epidermolysis Bullosa Simplex. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Generalized Epidermolysis Bullosa SimplexActive, not recruiting

Generalized Epidermolysis Bullosa SimplexPreclinical

Active, not recruiting

Competition

Competitive Landscape

1 competitor in Generalized Epidermolysis Bullosa Simplex

#DrugCompanyPhaseTrials

AC-203

TTWi Biotechnology, Inc.

Preclinical

1 2

Vehicle

TTWi Biotechnology, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

PreclinicalActive, not recruiting

Generalized Epidermolysis Bullosa Simplex

NCT06073132

Clinical

Trials by Indication[1]

Generalized Epidermolysis Bullosa Simplex1 trial

An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS) [EBShield Study]

Active, not recruiting·TTWi Biotechnology, Inc.·Preclinical·NCT06073132·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Vehicle. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Vehicle. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — TWi Biotechnology, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: TTWi Biotechnology, Inc.

Vehicle

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Generalized Epidermolysis Bullosa Simplex1 trial

References

Drug Info

Quick Facts

Related News